Navigation Links
CuraGen Presents Update on Clinical Development Program for,Belinostat

ng).

The Phase II portion of this trial for ovarian cancer has been initiated with 16 patients having been treated with 13 patients continuing on study and undergoing assessment to determine response to treatment. This trial utilizes a Simon Two Stage Design and is initially enrolling up to 18 patients. Two of the ongoing patients have achieved an objective response and upon confirmation the Company expects to expand the trial and enroll up to 32 patients to further define the objective response rate and tolerability of belinostat in combination with carboplatin and paclitaxel.

Furthermore, this Phase II study has been broadened to include an additional arm that will enroll up to 15 patients with transitional cell cancer of the bladder in order to evaluate the activity of belinostat in combination with carboplatin and paclitaxel in this patient population. Interim results are anticipated during the first half of 2008.

NCI P7267: Phase II trial evaluating intravenous belinostat monotherapy for micropapillary/borderline low malignant potential (LMP) ovarian carcinoma or advanced platinum resistant ovarian tumors

The Phase II trial is an open-label study evaluating belinostat as a single agent treatment for patients with either micropapillary/borderline LMP ovarian carcinoma or advanced platinum resistant ovarian tumors. The primary endpoint for the study is determination of objective response, as evaluated by RECIST and GCIG CA125 criteria. Secondary endpoints include evaluation of safety and tolerability of belinostat, stable disease rates, duration of response, progression-free survival, as well as median and overall survival. Enrollment of patients is ongoing into both arms of the trial. An objective clinical response has been recently observed in the LMP arm and is pending confirmation and review. This study is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen, and being conducted unde
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:7/31/2014)...  Zacks.com announces the list of stocks featured in the ... the latest news and events impacting stocks and the financial ... BIIB - Free Report ), Gilead (Nasdaq: GILD ... Free Report ), AbbVie (NYSE: ABBV - Free Report ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
(Date:7/31/2014)... AUSTIN, Texas , July 31, 2014 Vermillion, ... cancers and women,s health, will hold a conference call on ... discuss results for the second quarter ended June 30, 2014. ... to the call. Vermillion,s Chairman, President and CEO ... a question and answer period. Date: Thursday, August ...
(Date:7/31/2014)... TB Alliance, a not-for-profit with the ... affordable treatments, announced the appointment of Willo ... Mr. Brock comes to TB Alliance having most ... for WWF International (formerly known as the World ... guide the TB Alliance,s resource development, advocacy and ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6Vermillion Sets Second Quarter 2014 Conference Call for Thursday, August 14, 2014 2TB Alliance Appoints Willo Brock Senior Vice President, External Affairs 2
... June 14, 2011 Orthopedics This Week announced today ... News to supply Orthopedics This Week, the #1 source ... terminal subscribers including some of the most prominent investors ... The Bloomberg network includes portfolio managers, central bankers, finance ...
... 2011 Pacira Pharmaceuticals, Inc., (Nasdaq: PCRX ... the U.S. Food and Drug Administration (FDA) has extended ... for its review of the New Drug Application (NDA) ... The new PDUFA goal date is October 28, 2011. ...
Cached Medicine Technology:Orthopedics This Week Now on Bloomberg 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 2Pacira Pharmaceuticals, Inc. Announces FDA Extension of EXPAREL™ PDUFA Target Date by Three Months 3
(Date:7/31/2014)... 31, 2014 Dr. Andrew Lian-Jie Li ... of Dermatology, fellowship trained Mohs surgeon that has been ... , After extensive dermatology research training at the National ... Li completed his internship in internal medicine at the ... Pennsylvania in Philadelphia. Dr. Li pursued further training in ...
(Date:7/31/2014)... prevalence of heroin use has been rising steadily in ... Survey on Drug Use and Health, the number of ... 2007 (373,000) and 2012 (669,000). Emerging evidence suggests the ... who transition from oral and/or intranasal PO use to ... opioid use, and ultimately, heroin injection. This drug-use ...
(Date:7/31/2014)... Model moms are believers. PBS has a ... in the field have grown exponentially in the last two ... industry, there are associated myths that need to be busted. ... Frontier Nursing University . Celebrating 75 years in 2014, Frontier ... in the nation. “Frontier is changing the face of healthcare ...
(Date:7/31/2014)... UK (PRWEB) July 31, 2014 Infection ... the development and maintenance of products in the pharma, ... be performed by using various products and equipment types; ... spoilage of various materials and products. , The ... services is forecast to post a CAGR of about ...
(Date:7/31/2014)... By Amy Norton ... -- They may not have had fast food, TVs or ... arteries -- and a new research review speculates on some ... ancient Egypt, Peru, the Aleutian Islands and the American Southwest, ... of heart arteries from fatty substances that build up, eventually ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 2Health News:No TV or Obesity, But Ancient People Still Had Heart Disease 3
... group of immature cells that persist in the adult ... mice that these cells undergo dramatic changes in ALS, ... reported November 17 online in Neuron shows that these ... life, eventually morphing into mature nervous system cells called ...
... HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay News) -- ... a striking effect on lowering blood pressure in heart ... drugs, Australian researchers report. Although this study only ... -- the authors believe the approach, which involves delivering ...
... Nov. 17 (HealthDay News) -- A new drug focused on the ... clinical trials, new research shows. If eventually approved by ... VX-770 would mark the first treatment that gets at what ... than just the symptoms. Only 4 to 5 percent of ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- Resistance ... than aerobic exercise and offers other cardiovascular benefits, finds ... University in Boone, N.C., compared blood vessel (vascular) responses ... 10 repetitions of eight resistance exercises and 30 minutes ...
... 17 (HealthDay News) -- The U.S. Food and Drug Administration ... products are illegal. In warning letters to the companies, ... is an "unsafe food additive," and the companies risked further ... find support for the claim that the addition of caffeine ...
... to targeting diseases such as cancer has been announced by ... the potential for more targeted treatments following their identification of ... a human cell. The research teams from Germany and ... Publication on Nature Cell Biology ,s website. ...
Cached Medicine News:Health News:Mysterious cells may play role in ALS 2Health News:Nerve Zap to Kidneys Might Ease Stubborn Hypertension 2Health News:Nerve Zap to Kidneys Might Ease Stubborn Hypertension 3Health News:Drug Targets Faulty Process That Drives Cystic Fibrosis 2Health News:Drug Targets Faulty Process That Drives Cystic Fibrosis 3Health News:Resistance Exercise May Offer Different Cardio Benefits 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 2Health News:FDA Cracks Down on Caffeinated Alcohol Drinks 3Health News:Scientists announce new advance with potential for future cancer targeting 2
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
Contoured waterfall-front ergonomic seats and generous backrests with lumbar support are standard on these ergonomic chairs. • With casters • With Tubular Base....
... Bench high, 26-31". Ergonomic design increases ... pnuematic control for easy height adjustment. ... allow easy mobility. Fixed footring standard. ... 5000 Volts to technical zero); ...
Inquire...
Medicine Products: